US20040071792A1 - Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity - Google Patents

Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity Download PDF

Info

Publication number
US20040071792A1
US20040071792A1 US10/469,025 US46902503A US2004071792A1 US 20040071792 A1 US20040071792 A1 US 20040071792A1 US 46902503 A US46902503 A US 46902503A US 2004071792 A1 US2004071792 A1 US 2004071792A1
Authority
US
United States
Prior art keywords
extract
tilianin
agastache rugosa
activity
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/469,025
Other languages
English (en)
Inventor
Hyeong Lee
Sei Oh
Kyung Ahn
Soon Chol
Jung Kim
Goo Oh
Jung Hong
Seong Park
Woo Namkung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Assigned to KOREA RESEARCH INTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY reassignment KOREA RESEARCH INTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AHN, KYUNG SEOP, CHOI, SOON JA, HONG, JUNG JOO, KIM, JUNG HEE, LEE, HYEONG KYU, NAMKUNG, WOO, OH, GOO TAEG, OH, SEL RYANG, PARK, SEONG KYU
Publication of US20040071792A1 publication Critical patent/US20040071792A1/en
Priority to US11/802,527 priority Critical patent/US7534456B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a composition comprising Agastache rugosa and tilianin obtained therefrom by separation-purification for anti-inflammation and anti-atherosclerosis, and more particularly, to an extract of Agastache rugosa and tilianin obtained thereform by separation-purification which is effective in preventing and treating not only inflammatory diseases but also atherosclerosis related to inflammatory responses and disease in circulatory system caused by atherosclerosis because they are excellent in inhibiting the activity of complement system as a factor of inflammatory responses, the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecular-1 (VCAM-1), and the production of nitric oxide (NO). They can also significantly reduce the development of atherosclerosis due to inflammatory responses.
  • IAM-1 intercellular adhesion molecule-1
  • VCAM-1 vascular cell adhesion molecular-1
  • NO nitric oxide
  • inflammatory responses remove external sources of infection, reproduce damaged tissues, and recover the function of life, but when an antigen is not removed or inflammatory responses occur excessively or continuously due to intrinsic substances, inflammatory responses become the main pathological symptoms of diseases (hypersensitive disease, chronic inflammation) and the main obstacles in the processes of treatment such as blood transfusion, drug administration and organ transplantation, and the like.
  • Complement system is a major factor of body fluid, which activates and amplifies inflammation at the early stage of an immune response.
  • Active proteins anaphylatoxins ; C3a, C4a, C5a
  • conjugated proteins membrane attack complex (MAC)
  • MAC membrane attack complex
  • ICAM-1 is a typical protein of cell adhesion molecule group expressed on the surface of endothelial cells. Normally, it is expressed in a very low level, however, when it is stimulated by inflammation-mediating molecules of cytokines such as TNF- ⁇ , interferon- ⁇ , and interleukin-1 ⁇ , the level of expression is accelerated rapidly to play a role in adhering inflammatory cells such as monocytes or lymphocytes that move in blood and in moving the inflammatory cells to the inflammatory tissues. Therefore, the expression of ICAM-1 plays an important role in the amplification of inflammation when inflammatory cells move and gather on the inflammatory tissues at its early stage.
  • cytokines such as TNF- ⁇ , interferon- ⁇ , and interleukin-1 ⁇
  • VCAM-1 is one of cell adhesion molecule groups expressed on the surface of endothelial cells. The expression increases rapidly in the endothelial cells of blood vessels when atherosclerotic lesions are produced in the animal model (apolipoprotein E-deficient mice, ApoE-/-) analogous with the progress of human atherosclerosis. And the increase of VCAM-1 expression is directly correlated with the concentration of cholesterol—low density lipoprotein (cholesterol-LDL) in the plasma.
  • cholesterol-LDL cholesterol—low density lipoprotein
  • VCAM-1 expressed in the endothelial cells of blood vessels adheres monocytes and lymphocytes in the blood and those inflammatory cells gather under endothelial cells of blood vessels, thus playing an important role in development of atherosclerotic lesions.
  • NO is produced together with L-citrulline after L-arginine is oxidized by nitric oxide synthase (NOS).
  • NO is a mediating-molecule concerned with vasodepression, adhesion and coagulation of blood platelets, neurotransmission, movement of digestive organism, and erection of penis by affecting the blood vessel system.
  • NO protects against a microbial infection by being produced not only in inflammatory cells but also in noniimune cells.
  • the inducible-NOS (iNOS) one of NOS participating in producing NO is independent of calcium or calmodulin and expressed by stimulation of lipopolysaccharide (LPS) and cytokines (IFN- ⁇ , TNF and the like).
  • cyclooxygenase-2 (COX-2) is also activated by this stimulation thereby producing inflammation-mediating molecules, prostaglandins, there is close correlation between the expression of iNOS and COX-2, and thus produced NO also affects the expression of COX-2.
  • Production of NO in macrophages is selectively induced by the expression of iNOS, and thus induces activation of other inflammatory responses. Therefore, NO is an important factor of inflammatory diseases.
  • Atherosclerosis is a disease with arteries becoming hardened caused by genetic conditions related to lipid metabolism and environmental conditions such as eating habits, smoking and lack of exercise, and it can result in diseases of circulatory system such as a heart disease and a vascular disease of brain.
  • a hypothesis about early outbreak of atherosclerosis is “response-to-injury” hypothesis and this means that the endothelial cells of blood vessels become dysfunctioned by being unable to maintain normal homeostasis as the result of genetic changes, peroxides, hypertension, glycosuria, increase in plasma homocysteine concentration and microbial infection, and the like.
  • LDL low-density lipoprotein
  • MLDL modified-LDL
  • LDL is flowed and accumulated under the endothelial cells, and accumulated LDL and oxidized MLDL repeat the process of inducing inflow and activation of immunocytes such as macrophages, T-lymphocyte and the like, and consequently inflammation of lesion is promoted. Thereafter, the speck is necrotized by macrophage inflowed to the lesion, and hydrolase released from lymphocyte, inflammation-mediating factor and growth factor.
  • lesion tissue grows into a complex structure of fibrous tissues covered with fibroid materials in necrotic tissue having MLDL as a core part.
  • Thrombus is produced from the grown lesion tissue, arteries become hardened and diseases of circulatory system such as hindrance of blood flow occur. Therefore, atherosclerosis occurs when the amount of fat such as cholesterol and LDL in the blood is high, but it does not occur simply by accumulation of fat.
  • Atherosclerosis is a typical inflammatory response that endothelial cells, macrophages and lymphocytes correlate with a series of process of inflow and accumulation of fat under the endothelial cells of arteries, progress of lesion thereafter and finally cell necrosis.
  • Agastache rucosa is a perennial plant, which belongs to Labiatae family and is distributed in Northeast Asia that includes Korea, Japan, China, and etc. In Korea, it mostly grows wild in southern area or cultivated in some areas.
  • the aerial part of this plant is called Patcholi (other name of Agastache rugosa ) and a Chinese book, “Myoneubyolok”, says “it removes bad energy from our body and toxin by configuration of the ground, and cures cholera morbus, that is, cures one's sickness inside and intestinal convulsion”.
  • the leaf is used as a savor material in various soups such as loach soup and the flower is used as a honey source.
  • the inventors investigated anti-inflammatory and anti-atherosclerotic activity of drugs of natural origin used for food and medicinal purposes in order to select natural drugs that do not hinder normal lipid metabolism and are able to control the progress of atherosclerotic lesions caused by anti-inflammatory activity.
  • the present invention completed by finding that extract of Agastache rucosa has inhibitory activity against various inflammatory factors and excellent anti-atherosclerotic activity decreasing significantly atherosclerotic lesions related to inflammatory responses.
  • the object of the present invention is, therefore, to provide an extract of Agastache rugosa and tilianin obtained therefrom by separation-purification which is effective as drugs and food additives for preventing as well as treating inflammatory diseases, atherosclerosis which is related to inflammatory responses and diseases of circulatory system due to atherosclerosis because they have an anti-inflammatory activity and an anti-atherosclerotic activity.
  • FIG. 1 shows dose-dependent effect of tilianin on endothelial molecule induction.
  • HUVECs were preincubated with 10 or 100 ⁇ M tilanin for 2 hours and stimulated with TNF- ⁇ (10 ng/ ml) for 16 hours, stained for VCAM-1 or isotype control, and analyzed by flow cytometry.
  • FIG. 2 shows effect of Agastache rucosa extract on atherosclerotic lesions in Oil red O-stained aortic valve lesion areas of Ldlr-/-mice fed with a cholesterol diet for 8 weeks. Representative cross-sections of aortic valves ( ⁇ 100) in hearts from (A) control group and (B) 1% Agastache rucosa extract-diet group.
  • FIG. 3 shows immunochemical staining of the macrophage accumulation of aortic valve lesions ( ⁇ 100) from (A) control group and (B) 1% Agastache rucosa extract-diet group in the Ldlr-/-mice fed with a cholesterol diet for 8 weeks by using the monoclonal antibody to mouse macrophages-2 (MOMA-2, Serotec Inc. N.C. U.S.A).
  • MOMA-2 monoclonal antibody to mouse macrophages-2
  • FIG. 4 shows effect of tilianin on atherosclerotic lesions in aortic valve lesion areas of Ldlr-/-mice fed with a cholesterol diet for 8 weeks.
  • the present invention relates to a composition, which has an anti-inflammatory and anti-atherosclerotic activity comprising an extract of Agastache rugosa and tilianin obtained therefrom by separation-purification as an active ingredient.
  • the extract of Agastache rugosa or tilianin obtained by separation-purification has an inhibitory activity of inflammatory factors, i.e. an anti-complement activity, an inhibitory activity against the expression of ICAM-1 and VCAM-1, and an inhibitory activity against the production of NO, so it is effective for prevention and treatment of not only inflammatory diseases but also atherosclerosis due to its excellent inhibitory activity against atherosclerotic lesion related to inflammatory responses.
  • the present invention includes drugs or food additives comprising an extract of Agastache rugosa and tilianin obtained by separation-purification as an active ingredient.
  • the extract of Agastache rugosa is obtained by drying whole plant of Agastache rugosa , extracting it with low-grade alcohol followed by it concentration. Fractional yield of the extract is about 10 to 20% of weight of dried Agastache rugosa .
  • extract of Agastache rugosa is suspended in water, fractionated by n-hexane of the same volume after sufficient shaking and fractionated by chloroform and low grade alcohol added in this order, and then the fractions by solvent are obtained.
  • low-grade alcohol is alkyl-alcohol of 1 or 6 carbons, desirably n-butanol.
  • the fraction method by solvent is subject to conventional method such as column chromatography with silica gel and high-speed liquid chromatography. Or general separation-purification method such as recrystallization can be used.
  • the extract of Agastache rugosa has anti-complement activity which strongly inhibits complement activation of human serum against immune complex. And, it inhibits strongly expression of ICAM-1 against THP-1 monocytic leukemic cells (THP-1 cells) which induce ICAM-1 expression by tumor necrosis factor- ⁇ (TNF- ⁇ ). And, it has a strong inhibitory activity against NO production of mice's monocyte/macrophage RAW264.7 cells which were activated by lipopolysaccharide (LPS).
  • THP-1 monocytic leukemic cells THP-1 monocytic leukemic cells
  • TNF- ⁇ tumor necrosis factor- ⁇
  • LPS lipopolysaccharide
  • mice with carrageenan induced-acute inflammation shows strong anti-inflammatory activity in mice with carrageenan induced-acute inflammation and when low-density lipoprotein receptors-deficient mice (LDLR-/-mice) are bred with 1% of extract of Agastache rugosa added to the feed, atherosclerotic lesion decreased remarkably in aortic sinus of the control group.
  • LDLR-/-mice low-density lipoprotein receptors-deficient mice
  • the hexane fraction of extract of Agastache rugosa has strong anti-complement activity as described above and inhibitory activity against ICAM-1 expression
  • the chloroform fraction has strong inhibitory activity against ICAM-1 expression and inhibitory activity against NO production
  • the butanol fraction has strong inhibitory activity against ICAM-1 expression.
  • the method of preparing drugs and food additives accords with a well-known method because the present invention includes drugs and food additives comprising extract of Agastache rugosa and tilianin obtained by separation-purification as an active ingredient.
  • the extract of Agastache rugosa and tilianin can be used in themselves because they are natural form but they can also be made into powder, granule, capsule or injection mixed with carriers, forming agents, and diluents that are permitted pharmaceutically. Also the extract of Agastache rugosa has been used for foods and drugs from the old times and the dosage is not limited and can be varied according to internal absorbency, weight, patient's age, sex, health condition, administration time, administration method, excretion ratio, and degree of disease. Generally, the desirable amount of the extract of Agastache rugosa (concentrated state) and tilianin as an active ingredient is 0.1 ⁇ 100 mg/kg (weight). Therefore, the composition comprising active ingredients of the present invention must be prepared in consideration of limits of significant dosage and specialized administration is used or carried out several times with intervals upon necessity such as decision of an observer or an expert and requirement of each individual.
  • Drugs and food additives comprising the extract of Agastache rugosa and tilianin as active ingredients as described above are excellent in preventing and curing inflammatory diseases, atherosclerosis, and diseases of circulatory system due to atherosclerosis.
  • EA sensitized erythrocytes
  • Hemolysis ⁇ ⁇ Index ⁇ ⁇ ( % ) hemolysis ⁇ ⁇ aborbance ⁇ ⁇ of ⁇ ⁇ sample ⁇ ⁇ group - absorbance ⁇ ⁇ of ⁇ ⁇ sample ⁇ ⁇ only maximal ⁇ ⁇ hemolysis ⁇ ⁇ absorbance ⁇ ⁇ of ⁇ ⁇ reactive ⁇ ⁇ solution - absorbance ⁇ ⁇ of ⁇ ⁇ reactive ⁇ ⁇ solution ⁇ ⁇ only ⁇ 100
  • Activity ⁇ ⁇ of ⁇ ⁇ anti ⁇ - ⁇ complement ⁇ ⁇ ( % ) Hemolysis ⁇ ⁇ Index ⁇ ⁇ of ⁇ ⁇ Sample ⁇ ⁇ Group Hemolysis ⁇ ⁇ Index ⁇ ⁇ of ⁇ ⁇ Standard ⁇ 100
  • THP-1 cells were cultured in CO 2 incubator (5% CO 2 , 95% relative humidity, 37° C.) using RPMI-1640 broth (RPMI-1640, Gibco BRL 23400-021, 1.62%; 0.2% NaHCO 3 ; 1% antimicrobial agents with penicillin and streptomycin mixed) with 10% fetal bovine serum (Gibco BRL 26140-079, FBS) added to the culture media.
  • Samples for test were melted in DMSO, diluted with phosphate buffered saline solution (PBS) to below 5% and added to reactive solution by 5%, so as to set the concentration of DMSO with samples melted therein not to exceed 0.25% in the final solution.
  • PBS phosphate buffered saline solution
  • THP-1 cells 200 ⁇ l of THP-1 cells (2.5 ⁇ 10 5 cells/ml) was divided into each well of 96-well with addition of 10 ⁇ l of solution prepared at constant concentration. After culturing it in 37° C. CO, incubator for 1 hour, TNF- ⁇ (final concentration: 10 ng/mm) was added to induce ICAM-1 expression and it was cultured in CO 2 incubator for 16 more hours.
  • the reactive solution was made to isolate nonspecific bonding part by adding 25 ⁇ l of glutaraldehyde buffer solution (glutaraldehyde 2.08% in PBS) to set cells at well, washing it with PBST (0.005% tween-20 in PBS) and adding 3% skim milk.
  • the inhibitory activity against ICAM-1 expression of the extract of Agastache rugosa , solvent fraction thereof and tilianin was lower than dexamethasone, known as anti-inflammation agent, but particularly the n-hexane fraction and the chloroform fraction show excellent inhibitory activity.
  • dexamethasone has an excellent effect as a steroid agent
  • side effects disfunction of kidney, increase of inflammation, glycosuria, contraction of muscle, growth inhibition, osteoporosis, etc.
  • the extract of Agastache rugosa and tilianin are free from these side effects.
  • HUVECs were cultured in CO 2 incubator (5% CO 2 , 95% relative humidity, 37° C.) using EGM-2 Bulletkit broth [Kit which contains a 500 ml bottle of Endothelial Cell Basal Medium-2 (EBM-2, Clonetics CC-3156, Md., U.S.A)] with 100 U/ml of penicillin and 100 ⁇ g/ml of streptomycin added. Samples for test were melted in DMSO, concentration of which to remain below 0.1% in the final reactive solution. HUVECs were used as much as two culture dish ( ⁇ 10 cm, 2 ⁇ 10 6 cells) for each group, and the broth was exchanged prior to treatment of samples.
  • EGM-2 Bulletkit broth which contains a 500 ml bottle of Endothelial Cell Basal Medium-2 (EBM-2, Clonetics CC-3156, Md., U.S.A)] with 100 U/ml of penicillin and 100 ⁇ g/ml of streptomycin added. Samples for test were melted in
  • tilianin was preheated with final concentration of 100 ⁇ M and 10 ⁇ M for 2 hours. Then, TNF- ⁇ was treated to become 10 ng/ml for each group and VCAM-1 expression was induced for 16 hours. After being washed with PBS two times and trypsinized (0.025%) for 5 minutes, cells were collected. After the collected cells were centrifuged in 15 ml tubes, the upper solution was removed, cell precipitates were suspended with PBS, and the cells were centrifuged again and washed.
  • Inhibition ⁇ ⁇ ratio ⁇ ⁇ of ⁇ ⁇ VCAM ⁇ - ⁇ 1 ⁇ ⁇ expression ⁇ ⁇ ( % ) ( 1 - mean ⁇ ⁇ value ⁇ ⁇ of ⁇ ⁇ fluorescent ⁇ ⁇ intensity ⁇ ⁇ of ⁇ ⁇ sample ⁇ ⁇ group mean ⁇ ⁇ value ⁇ ⁇ of ⁇ ⁇ fluorescent ⁇ ⁇ intensity ⁇ ⁇ of ⁇ ⁇ control ⁇ ⁇ group ) ⁇ 100
  • RAW264.7 cells were incubated in CO 2 incubator (5% CO 2 , 95% relative humidity, 37° C.) for 48 hours after adding LPS (10 ⁇ g/ml) to RAW264.7 cells which were cultured in Dulbecco's Modified Eagle's medium (Gibco BRL, USA, 100 U/ml of penicillin and 100 ⁇ g/ml of streptomycin, 10% FBS, 6 g/L of HEPES, 3.7 g/L of NaHCO 3 ), and inducing activation.
  • LPS 10 ⁇ g/ml
  • Dulbecco's Modified Eagle's medium Gibco BRL, USA, 100 U/ml of penicillin and 100 ⁇ g/ml of streptomycin, 10% FBS, 6 g/L of HEPES, 3.7 g/L of NaHCO 3
  • Inhibition ⁇ ⁇ ratio ⁇ ⁇ of ⁇ ⁇ edema ⁇ ⁇ ( % ) 1 - Mean ⁇ ⁇ value ⁇ ⁇ of ⁇ ⁇ increase ⁇ ⁇ of ⁇ ⁇ sole ⁇ ⁇ sickness ⁇ ⁇ in ⁇ ⁇ sample ⁇ ⁇ group Mean ⁇ ⁇ value ⁇ ⁇ of ⁇ ⁇ increase ⁇ ⁇ of ⁇ ⁇ sole ⁇ ⁇ thickness ⁇ ⁇ in ⁇ ⁇ control ⁇ ⁇ group ⁇ 100
  • Table 5 indicates anti-inflammatory activity of the extacts of Agastache rugosa in carrageenan-induced acute inflammation model.
  • the extacts of Agastache rugosa showed strong anti-inflammatory activity from 2 hours of administration, and the inhibition effect against edema lasted for 5 hours of measurement.
  • TABLE 5 Time after Edema volume Inhibition rate of Sample treatment (hour) (%) edema (%) Extacts 0 100 — Agastache rugosa 1 100 — (200 mg/kg, p.o.) 2 45.8 54.2** 3 63.4 36.6* 4 60.8 39.2* 5 68.4 31.6*
  • Step I Mouse Breeding and Experiment on Administration of the Agastache rugosa to the Mouse
  • mice were randomly divided into two groups of 10, respectively.
  • One group was fed on a high cholesterol diet (15% fat, 1.25% cholesterol, 0.5% Na-cholate) and the other group was fed on the above diet mixed with supplement of 0.1% and 1% of sample for test.
  • the mice had free access to water and food.
  • Inhibition ⁇ ⁇ ratio ⁇ ⁇ of ⁇ ⁇ edema ⁇ ⁇ ( % ) 1 - Mean ⁇ ⁇ size ⁇ ⁇ of ⁇ ⁇ lesion ⁇ ⁇ of ⁇ ⁇ sample ⁇ ⁇ group Mean ⁇ ⁇ size ⁇ ⁇ of ⁇ ⁇ lesion ⁇ ⁇ of ⁇ ⁇ control ⁇ ⁇ group ⁇ 100 ( wherein , control ⁇ ⁇ group ⁇ ⁇ means ⁇ ⁇ high ⁇ ⁇ cholesterol ⁇ ⁇ diet ⁇ ⁇ group )
  • Tablets were prepared by the direct tableting method after crushing and mixing 10 g of the extract of Agastache rugosa (including 1 g of tilianin), 70 g of lactose, 15 g of crystalline cellulose and 5 g of magnesium stearate. The total amount of each tablet was 100 mg and the amount of extract of Agastache rugosa as an active ingredient was 10 mg (1 mg of tilianin).
  • Powder was prepared by crushing and mixing 10 g of the extract of Agastache rugosa (including 1 g of tilianin), 50 g of corn starch and 40 g of carboxycellulose. And capsules were prepared by putting 100 mg of powder into capsules with hardness VI.
  • Plum extract plum solid extract (solids amount 69°Bx, maker: Hadong National Agricultural Cooperative Federation in Korea), a Chinese quince, a Angelica gigas Nakai, a dried ginger, Maximowiczia chinesis , a cinnamon (Kyongdong Market, Seoul), grape juice (solids amount 65° Bx, maker: Comax international Corp.), and pear juice (maker : Hanmi aromatics chemistry) were prepared as ingredients for drink including the extract of Agastache rugosa.
  • the plum extract was used with the plum solid extract (69° Bx) diluted to 10° Bx, the grape juice (65Bx°), and pear juice (69Bx°) were used as undiluted.
  • ingredients for drink including the extract of Agastache rugosa, 0.1% extract of Agastache rugosa, 0.2% plum extract, 0.3% the extract of dried ginger, 0.3% the extract of Chinese quince, 0.01% the extract of cinnamon, 5.0% pear juice, and 17% superfructose were diluted in water to set to 100 ml, irradiated and treated at 95° C. for 15 seconds to prepare goods of drink type.
  • the extract of Agastache rugosa and tilianin obtained by separation-purification according to the present invention inhibit activation, production, and expression of various inflammatory factors, have the anti-inflammatory activity in animals and significant inhibitory activity against production of atherosclerotic lesion, therefore, they are useful as drugs or food additives for preventing or treating inflammatory diseases, atherosclerosis which is related to inflammatory responses and a disease of circulatory system due to atherosclerosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
US10/469,025 2001-02-27 2001-12-20 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity Abandoned US20040071792A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/802,527 US7534456B2 (en) 2001-02-27 2007-05-23 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2001-997702-27-01 2001-02-27
KR20010009977 2001-02-27
PCT/KR2001/002224 WO2002074320A1 (en) 2001-02-27 2001-12-20 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/802,527 Division US7534456B2 (en) 2001-02-27 2007-05-23 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity

Publications (1)

Publication Number Publication Date
US20040071792A1 true US20040071792A1 (en) 2004-04-15

Family

ID=19706307

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/469,025 Abandoned US20040071792A1 (en) 2001-02-27 2001-12-20 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity
US11/802,527 Expired - Fee Related US7534456B2 (en) 2001-02-27 2007-05-23 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/802,527 Expired - Fee Related US7534456B2 (en) 2001-02-27 2007-05-23 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity

Country Status (8)

Country Link
US (2) US20040071792A1 (ja)
EP (1) EP1363648B8 (ja)
JP (1) JP4091436B2 (ja)
KR (1) KR100447948B1 (ja)
CN (1) CN100376255C (ja)
CA (1) CA2439430C (ja)
DE (1) DE60124591T2 (ja)
WO (1) WO2002074320A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003030A1 (en) * 2004-07-01 2006-01-05 Lin Chun-Ying Essential oils for treating and/ or preventing allergic disease
KR100851489B1 (ko) * 2006-11-30 2008-08-08 (주)아모레퍼시픽 틸리아닌( ｔｉｌｉａｎｉｎ) 또는아카세틴(ａｃａｃｅｔｉｎ)을 유효성분으로 함유하는화장료 조성물
US20170361243A1 (en) * 2015-01-06 2017-12-21 Luterion Co., Ltd. Luterion and separating and culturing methods for same
CN111171094A (zh) * 2018-11-13 2020-05-19 上海医药工业研究院 一种香清兰苷中间体及其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100807645B1 (ko) * 2006-10-17 2008-02-28 주식회사 유니젠 위장질환 치료 및 예방용 조성물 및 그의 제조방법
DE202008011721U1 (de) * 2008-09-03 2008-12-24 American Phoenix Biotech Inc., Hacienda Heights Pflanzliche Zusammensetzung zur Behandlung von Krebs
KR101540310B1 (ko) * 2013-08-07 2015-07-30 건국대학교 산학협력단 방아풀 추출물을 함유하는 신경 염증 예방 및 치료용 조성물, 그리고 방아풀 추출물 추출 방법
PL412214A1 (pl) 2015-05-04 2016-11-07 Biovico Spółka Z Ograniczoną Odpowiedzialnością Kompozycja roślinna o właściwościach przeciwzapalnych, przeciwalergicznych i/lub przeciwastmatycznych oraz jej zastosowanie
KR102049875B1 (ko) 2018-06-29 2019-11-28 충북대학교 산학협력단 에키나세아 배양근 유래 신규 화합물 및 이의 항염증 용도
KR102339923B1 (ko) * 2019-11-12 2021-12-20 한국한의학연구원 혈행 개선용 식치제호탕 조성물
KR102300732B1 (ko) * 2020-11-11 2021-09-14 주식회사 제이에스무역 난황유 및 배초향 줄기세포를 함유하는 항산화, 미백, 항주름 또는 항염증용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3831196A1 (de) * 1988-09-14 1990-03-22 Bosch Gmbh Robert Elektromagnetisch betaetigbares ventil
CN1060772A (zh) * 1991-10-30 1992-05-06 阳山县食品厂 一种藿香姜计陈皮的生产工艺
CN1057447C (zh) * 1993-01-22 2000-10-18 马军营 一种治疗小儿腹泻的口服液
CN1117388A (zh) * 1994-08-24 1996-02-28 东营市面粉厂 复方柴胡擦剂
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
KR970007366A (ko) * 1995-07-31 1997-02-21 고제섭 압축단자 접촉저항 측정장치 및 그 방법
CN1151881A (zh) * 1995-12-01 1997-06-18 陶周行 一种阴道冲洗保留剂及其制备工艺与使用方法
WO1998013055A1 (fr) * 1996-09-27 1998-04-02 Takeshi Karita Composition antioxydante destinee a intercepter des radicaux libres, composition pharmaceutique comprenant celle-ci, et leur procede de preparation
US5776462A (en) * 1996-12-10 1998-07-07 Sage R&D, A Partnership Pogostemon cablin extract for inhibiting H. influenzae adhesion and treating otitis media or sore throat
KR100232053B1 (ko) * 1997-04-22 1999-12-01 김동태 DPPH(1,1-diphenyl-2-picrylhydrazyl)를 이용한 항산화물질의 분석방법
JP4231559B2 (ja) * 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
KR100215400B1 (ko) * 1997-05-27 1999-08-16 김진수 건강보조식품용 유중수적형 영양음료 및 그 제조방법
KR100309071B1 (ko) * 1998-09-02 2001-12-17 성재갑 콜라겐합성촉진제를함유한피부용조성물
KR100341798B1 (ko) * 1999-08-04 2002-06-26 대한민국 (관리청:특허청장, 승계청:농촌진흥청장) 방아잎으로부터 로즈마린산을 분리하는 방법
AU2446801A (en) * 1999-12-23 2001-07-03 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
KR100376306B1 (ko) * 2000-08-07 2003-03-17 한완석 혈액순환 촉진용 건강식품 조성물
CN1126453C (zh) * 2000-08-09 2003-11-05 郭兴华 天然抗菌组合物及其应用
CN1282537A (zh) * 2000-08-22 2001-02-07 张益� 一种藿香饮料

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003030A1 (en) * 2004-07-01 2006-01-05 Lin Chun-Ying Essential oils for treating and/ or preventing allergic disease
KR100851489B1 (ko) * 2006-11-30 2008-08-08 (주)아모레퍼시픽 틸리아닌( ｔｉｌｉａｎｉｎ) 또는아카세틴(ａｃａｃｅｔｉｎ)을 유효성분으로 함유하는화장료 조성물
US20170361243A1 (en) * 2015-01-06 2017-12-21 Luterion Co., Ltd. Luterion and separating and culturing methods for same
US10569194B2 (en) * 2015-01-06 2020-02-25 Luterion Co., Ltd. Luterion and separating and culturing methods for same
CN111171094A (zh) * 2018-11-13 2020-05-19 上海医药工业研究院 一种香清兰苷中间体及其制备方法和应用

Also Published As

Publication number Publication date
DE60124591D1 (de) 2006-12-28
EP1363648A1 (en) 2003-11-26
CA2439430A1 (en) 2002-09-26
US20080081081A1 (en) 2008-04-03
JP2004521933A (ja) 2004-07-22
KR20020070062A (ko) 2002-09-05
US7534456B2 (en) 2009-05-19
KR100447948B1 (ko) 2004-09-08
WO2002074320A1 (en) 2002-09-26
EP1363648A4 (en) 2005-02-09
EP1363648B1 (en) 2006-11-15
CA2439430C (en) 2010-06-22
CN1518454A (zh) 2004-08-04
DE60124591T2 (de) 2007-09-06
EP1363648B8 (en) 2007-04-25
CN100376255C (zh) 2008-03-26
JP4091436B2 (ja) 2008-05-28

Similar Documents

Publication Publication Date Title
US7534456B2 (en) Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity
CN102292093B (zh) 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
JP2008174539A (ja) 紫色の馬鈴薯を使用した肥満患者用の健康機能食品
KR20160041138A (ko) 갈색거저리 유충의 추출물 또는 갈색거저리 유충의 현탁액을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
KR20100122333A (ko) 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
KR101965061B1 (ko) 땅콩 새싹 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물
JP2021052753A (ja) 健康な妊産婦の母乳由来嫌気性ヒト菌株及びそれを用いた代謝性疾患の予防又は治療方法
KR101735057B1 (ko) 오스모틴 단백질 또는 오스모틴 펩타이드를 유효성분으로 함유하는 간기능 및 신장기능 장애의 예방 또는 치료용 조성물
KR100865513B1 (ko) 강화약쑥 알코올 추출물을 포함하는 비만의 예방 및 치료용 조성물
KR102438938B1 (ko) 바이탈멜론 (kctc14699bp) 및 이의 추출물을 포함하는 항비만용 조성물
CN100488533C (zh) 一种用于治疗和改善支气管呼吸困难的草药组合物
WO2018066956A1 (ko) 오미자를 함유하는 복합 추출물을 포함하는 혈액순환 관련 질환의 예방 또는 치료용 조성물
KR100454087B1 (ko) 항동맥경화 활성을 나타내는 틸리아닌
KR100460439B1 (ko) 배초향 추출물이 함유된 식품첨가제
US9526717B2 (en) Composition for treating immune diseases containing daurinol compound as active ingredient
KR20010007625A (ko) 디오스민을 포함하는 동맥경화증 및 고지혈증의 예방 및치료용 조성물
KR20130046094A (ko) 어저귀 추출물을 포함하는 염증성질환 예방 또는 치료용 의약 조성물
US20180125903A1 (en) Pharmaceutical composition containing portulaca grandiflora hook. extract or fraction thereof as active ingredient for preventing or treating neuroinflammation or neuro-degenerative diseases
WO2000032214A1 (en) Preventives for hepatopathy
KR20020082121A (ko) 플라보놀 유도체를 유효성분으로 함유하는 간염 예방 또는치료용 약학적 조성물
Obeten et al. EVALUATION OF AQUEOUS EXTRACT OF VERNONIA AMYGDALINA ON THE HISTOPATHOLOGY OF THE LIVER OF WISTAR RATS
KR20040027100A (ko) 대황 추출물을 함유하는 고지혈증 치료제 조성물
Widyasti Chemical constituents of fan-si abutilon indicum stems
KR20240079612A (ko) 팥 추출물을 포함하는 비알코올성 지방간 예방, 개선 또는 치료용 조성물
CN100409863C (zh) 双黄连在制备治疗动脉粥样硬化药物中的应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: KOREA RESEARCH INTITUTE OF BIOSCIENCE AND BIOTECHN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, HYEONG KYU;OH, SEL RYANG;AHN, KYUNG SEOP;AND OTHERS;REEL/FRAME:014750/0419

Effective date: 20030818

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION